Related Experiment Video

Updated: Aug 30, 2026

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity
04:20

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity

Published on: February 9, 2024

AAF-cmk sensitizes tumor cells to trail-mediated apoptosis

Izabela Młnarczuk1, Paweł Mróz, Grazyna Hoser

  • 1Department of Immunology, Center of Biostructure, The Medical University of Warsaw, Chalubińskiego 5, 02004 Warsaw, Poland.

Leukemia Research
|November 25, 2003
PubMed

Insights

Ala-Ala-Phe-chloromethylketone (AAF-cmk) enhances the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and tumor necrosis factor (TNF) cytotoxic effects on human leukemia cells. This potentiation is primarily mediated by apoptosis, suggesting AAF-cmk as a potential sensitizing agent.

Area of Science:

  • Oncology
  • Immunology
  • Cell Biology

Background:

  • Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) exhibits cytotoxicity against tumor cells but can also affect normal cells.
  • Enhancing the antitumor efficacy of TRAIL and tumor necrosis factor (TNF) requires identifying potentiation agents.
  • Leukemia cells present a significant therapeutic challenge, necessitating novel treatment strategies.

Purpose of the Study:

  • To investigate the potential of Ala-Ala-Phe-chloromethylketone (AAF-cmk) to augment the cytotoxic effects of TRAIL and TNF.
  • To determine the mechanism by which AAF-cmk influences TRAIL- and TNF-mediated cytotoxicity.
  • To evaluate AAF-cmk as a sensitizing agent for human leukemia cells.

Main Methods:

  • Treatment of human leukemic cells with TRAIL or TNF in combination with AAF-cmk.
  • Flow cytometry analysis to assess apoptosis induction.
  • Electron microscopy to examine cellular ultrastructure and confirm apoptosis.

Main Results:

  • AAF-cmk significantly augmented the cytotoxic activity of TRAIL and TNF against human leukemic cells.
  • Apoptosis was identified as the primary mechanism responsible for the observed potentiation.
  • The combination therapy demonstrated enhanced apoptotic induction in leukemia cells.

Conclusions:

  • AAF-cmk effectively sensitizes human leukemia cells to apoptosis induced by TRAIL and TNF.
  • This study highlights the potential of AAF-cmk as an adjuvant therapy to enhance the efficacy of TRAIL and TNF in leukemia treatment.
  • Further research into AAF-cmk's role in cancer therapy is warranted.

More Related Videos

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...